Unknown

Dataset Information

0

Risk of Cardiac Events Associated With Antidepressant Therapy in Patients With Long QT Syndrome.

ABSTRACT: Patients with long QT syndrome (LQTS) are at a high risk of cardiac events. Many patients with LQTS are treated with antidepressant drugs (ADs). We investigated the LQTS genotype-specific risk of recurrent cardiac arrhythmic events (CAEs) associated with AD therapy. The study included 59 LQT1 and 72 LQT2 patients from the Rochester-based LQTS Registry with corrected QT (QTc) prolongation and a history of AD therapy. Using multivariate Anderson-Gill models, we estimated the LQTS genotype-specific risk of recurrent CAEs (ventricular tachyarrhythmias, aborted cardiac arrest, or sudden cardiac death) associated with time-dependent ADs. Specifically, we examined the risk associated with all ADs, selective serotonin reuptake inhibitor (SSRI), and ADs classified on the CredibleMeds list (www.CredibleMeds.org) as "Conditional" or "Known risk of Torsades de pointes (TdP)." After adjusting for baseline QTc duration, sex, and time-dependent beta-blocker usage, there was an increased risk of recurrent CAEs associated with ADs in LQT1 patients (hazard ratio?=?3.67, 95% confidence interval 1.98-6.82, p?

SUBMITTER: Wang M 

PROVIDER: S-EPMC5742310 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Risk of Cardiac Events Associated With Antidepressant Therapy in Patients With Long QT Syndrome.

Wang Meng M   Szepietowska Barbara B   Polonsky Bronislava B   McNitt Scott S   Moss Arthur J AJ   Zareba Wojciech W   Auerbach David S DS  

The American journal of cardiology 20171113 2

Patients with long QT syndrome (LQTS) are at a high risk of cardiac events. Many patients with LQTS are treated with antidepressant drugs (ADs). We investigated the LQTS genotype-specific risk of recurrent cardiac arrhythmic events (CAEs) associated with AD therapy. The study included 59 LQT1 and 72 LQT2 patients from the Rochester-based LQTS Registry with corrected QT (QT<sub>c</sub>) prolongation and a history of AD therapy. Using multivariate Anderson-Gill models, we estimated the LQTS genoty  ...[more]

Similar Datasets

Unknown Risk of cardiac events in Long QT syndrome patients when taking antiseizure medications.
| S-EPMC5733703 | biostudies-literature
Unknown Risk of life-threatening cardiac events among patients with long QT syndrome and multiple mutations.
| S-EPMC3690288 | biostudies-literature
Unknown Mutation and gender-specific risk in type 2 long QT syndrome: implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome.
| S-EPMC4028036 | biostudies-literature
Unknown Stop-codon and C-terminal nonsense mutations are associated with a lower risk of cardiac events in patients with long QT syndrome type 1.
| S-EPMC4743743 | biostudies-literature
Unknown Genotype-specific QT correction for heart rate and the risk of life-threatening cardiac events in adolescents with congenital long-QT syndrome.
| S-EPMC3641882 | biostudies-literature
Unknown Autonomic and Cardiac Repolarization Lability in Long QT Syndrome Patients.
| S-EPMC7704776 | biostudies-literature
Unknown Long QT syndrome: from channels to cardiac arrhythmias.
| S-EPMC1180552 | biostudies-literature
Unknown Arrhythmia phenotype during fetal life suggests long-QT syndrome genotype: risk stratification of perinatal long-QT syndrome.
| S-EPMC4151528 | biostudies-other
Unknown Characterization of N-terminally mutated cardiac Na(+) channels associated with long QT syndrome 3 and Brugada syndrome.
| S-EPMC3693076 | biostudies-literature
Unknown "QT clock" to improve detection of QT prolongation in long QT syndrome patients.
| S-EPMC4698188 | biostudies-literature